Skip to content

HR-HPV Multi-site Opportunistic Screening in Liaoning, China

HR-HPV Multi-site Opportunistic Screening in Liaoning, China

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03178136
Enrollment
10000
Registered
2017-06-06
Start date
2017-06-19
Completion date
2022-06-30
Last updated
2019-01-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Cancer

Keywords

HR-HPV opportunistic screening, virus load, multi-site

Brief summary

It is universally accepted that the persistent infection of high-risk human papillomavirus(HR-HPV) is the cause of cervical intraepithelial neoplasias and cancer. Some researches indicate that the virus load may relate the extent of the disease. The objective of the study is to detect the virus load of 14 types HR-HPV among the participants, using a new HPV DNA hybrid capture technology,sequentially find the diagnostic significance of virus load of HPV.

Detailed description

Cervical cancer is the most common malignancy in women, the persistent infection of high-risk human papillomavirus(HR-HPV) is the definite cause,especially the infection of human papillomavirus 16/human papillomavirus 18(HPV16/HPV18). Some researches indicate the virus load may relate the extent of the disease, but the sample capacity is not enough to receive a conclusive conclusion. And a specific quantity or a range of virus load which closely relates to cervical intraepithelial neoplasia 2(CIN2) or worse is not studied. The aim of the study is to prove the association between the virus load and development of cervical intraepithelial neoplasias by detecting 14 types HR-HPV, and find the specific quantitative value or the range to assist physician to diagnose. A detect reagent named Dalton hybrid 3(DH3) is used in the study, the mechanism of which is HPV DNA hybrid capture technology, the experimental process include seven steps, denaturation, hybridization, the formation of DNA-RNA heterozygote, capture, detect, rinse panel, read data. Study design: The organizations of the study contain ten hospitals in Liaoning province in China,patients accord with inclusion criteria(N=10000) sign informed consent and fill out a information form. Gynecologist collect cervical cell with sampling instrument. Detecting the virus load of HPV16/HPV18 and other 12 types HR-HPV, the positive result is cut-off ≥1.0pg/ml, HPV16/HPV18(+) need colposcopy. The abnormal result of colposcopy requires biopsy, the participant who has abnormal result of biopsy need operative treatment. Follow-up observation of all participants lasting 5 years are required.

Interventions

None listed

Sponsors

First Hospital of China Medical University
CollaboratorOTHER
Shenyang women's and children's hostipal
CollaboratorUNKNOWN
Dalian Medical University
CollaboratorOTHER
The Second Affiliated Hospital of Dalian Medical University
CollaboratorOTHER
Dandong women's and children's hostipal
CollaboratorUNKNOWN
The First People's Hospital of Jingzhou
CollaboratorOTHER
The second hospital of Chaoyang City
CollaboratorUNKNOWN
Women's and children's hospital of Yingkou City
CollaboratorUNKNOWN
Cancer hospital of Anshan City
CollaboratorUNKNOWN
Hangzhou Dalton Biosciences,LtD
CollaboratorUNKNOWN
Min Wang
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
25 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

The patients who are voluntary to accept screening with sexual life

Exclusion criteria

uterectomy, cancer, other serious illness, physical examination(pregnant women are not exclusive)

Design outcomes

Primary

MeasureTime frameDescription
virus load1 dayvirus load of 14 types HR-HPV

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 15, 2026